Navigation Links
Landmark trial to evaluate cardioprotective properties of insulin
Date:11/9/2007

BUFFALO, N.Y. -- The ability of insulin to limit heart-tissue damage during a heart attack will be tested in a landmark clinical trial led by Paresh Dandona, M.D., Ph.D., University at Buffalo Distinguished Professor in the departments of Medicine and Pharmacology and Toxicology in the UB School of Medicine and Biomedical Sciences.

Approximately 600 patients at 90 centers in the U.S. and Latin America will be recruited to participate in the two-year INTENSIVE (Intensive Insulin Therapy and Size of Infarct as a Validated Endpoint by Cardiac MRI) trial. Patients in the trial, which is funded by sanofi-aventis, will be treated with two forms of insulin -- insulin glargine and insulin glulisine.

Kaleida Healths Diabetes-Endocrine Center of Western New York, which Dandona directs, will be one of the vanguard centers. The centers research facility, located in UBs New York State Center of Excellence in Bioinformatics and Life Sciences, will serve as the core laboratory.

Richard W. Nesto, M.D., associate professor at Harvard Medical School and chair of cardiovascular medicine at Lahey Clinic Medical Center in Burlington, Mass., will be co-principal investigator, directing the trials cardiovascular aspects.

The trial is based on a pilot study conducted by the diabetes center, which documented that insulin, used to treat and control type 1 and type 2 diabetes, was also cardioprotective.

This pilot study, published in the journal Circulation in 2004, was conducted in 32 patients receiving low-dose insulin. C-reactive protein (CRP) and serum amyloid A (SAA), two critical markers of inflammation, were reduced by 40 percent and 50 percent, respectively, during the 48 hours following a heart attack. Concentrations of three additional inflammatory factors also were significantly lower in those who received insulin, compared to those who did not.

The markers of myocardial damage that we measured were reduced significantly, said Dandona.
'/>"/>

Contact: Lois Baker
ljbaker@buffalo.edu
716-645-5000 x1417
University at Buffalo
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Document Security Systems (Amex: DMC) Invites You to a Landmark Event
2. Less than one-third of women aware of landmark hormone therapy study, Stanford researcher finds
3. Pathway to cell death redefined in landmark study
4. Pathway to cell death redefined in landmark study
5. UCLA to lead local study center in landmark government study of child health
6. Landmark Report: Excess Body Fat Causes Cancer
7. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
8. New Heart Pump Shows Promise in Trial
9. Trial to Test Gene Therapy for Angina in Women
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. The New England Journal of Medicine Publishes EURIDIS/ADONIS Study Results Showing Dronedarone Maintained Sinus Rhythm in Patients With Atrial Fibrillation or Flutter With no Observed Pro-Arrhythmia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , ... August 04, 2015 , ... ... products, announces the Assisted Dumbbell Bench Rack, a fitness invention that eliminates the ... , "The Gym, Health and Fitness Clubs industry is worth $30 billion," says ...
(Date:8/4/2015)... ... August 04, 2015 , ... The United Nations ... and rights in Indonesia for a select group of U.S.-based journalists during the ... Indonesia and attend the International Conference on Family Planning in Bali. , ...
(Date:8/4/2015)... ... ... An article published July 27th by the Providence Journal detailed ... people to lose weight. Specifically the study compared control patients with those who were ... financial incentive to the overall incentive of increased health. According to Michael Feiz, M.D., ...
(Date:8/4/2015)... Santa Barbara, CA (PRWEB) , ... August 04, ... ... if you are suffering from underarm sweat. Evolutions Medical & Day Spa in ... called miraDry, the only non-invasive, FDA cleared treatment that permanently eliminates sweat and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th Annual ... 3 – 4, 2015, at UC San Diego, will explore innovations that farmers ... access, and manage resources efficiently against the dueling backdrop of a lingering Western ...
Breaking Medicine News(10 mins):Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices in China with a rapidly growing,international presence, ... for the first quarter ended March 31, 2008, ... Mindray,s management will hold an earnings,conference call at ...
... They either miss shots or get them at the wrong ... -- New numbers show that more than a quarter of ... aged 19 months to 35 months found that missed doses ... miss-timed doses are also an issue, according to a study ...
... Increase of 47% Over Prior Year Period and ... Exceeds Guidance ... ) today reported the results for its third quarter and nine,months of ... Total revenues increased 9% to a record,level of $20.6 million in the ...
... Presentation System Designed for Today,s Younger Market, ... in,providing long-term care insurance sales, marketing and presentation,solutions ... of,simplifyingLTC, a LTCI presentation system designed specifically for,today,s ... the risk of long-term care in,a language younger ...
... Driven by International Growth and InLight Product Sales, GLENWOOD, ... recognized leader in personal and environmental radiation,monitoring, today reported that ... the three and six months ended March 31, 2008., ... record $23.7 million on InLight equipment sales and ...
... Deliver ... Advanced Imaging Services, POWAY, Calif., April ... of medical diagnostic imaging systems,and services to physicians, offices, hospitals ... agreement with the University of,Chicago Medical Center (Medical Center) to ...
Cached Medicine News:Health News:Mindray to Report First Quarter 2008 Financial Results on May 7, 2008 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 2Health News:1 in 4 U.S. Toddlers Improperly Vaccinated 3Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 2Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 3Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 4Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 5Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 6Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 7Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 8Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 9Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 10Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 11Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 12Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 13Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 14Health News:Kensey Nash Reports Third Quarter Record Revenue and Sales 15Health News:SellingLTC.com Develops simplifyingLTC 2Health News:Landauer, Inc. Reports Record Results for Second Quarter 2Health News:Landauer, Inc. Reports Record Results for Second Quarter 3Health News:Landauer, Inc. Reports Record Results for Second Quarter 4Health News:Landauer, Inc. Reports Record Results for Second Quarter 5Health News:Landauer, Inc. Reports Record Results for Second Quarter 6Health News:Landauer, Inc. Reports Record Results for Second Quarter 7Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 2Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 3Health News:Digirad Corporation and University of Chicago Medical Center Sign Letter of Agreement 4
(Date:8/4/2015)... -- Research and Markets ( ... "MRI Systems Market to 2020 - Focus ... Driven by Developing Economies" report to their ... - Focus on Patient Comfort and Operational Efficiency, ... market, competitive landscape, and trends for three MRI ...
(Date:8/4/2015)...  The Pittsburgh Life Sciences Greenhouse (PLSG), the region,s ... one of its portfolio companies, Medrobotics Corporation, has received ... Robotic System in the U.S.  "I ... said John W. Manzetti , president and CEO ... since spinning out of The Robotics Institute at Carnegie ...
(Date:8/4/2015)... PARK, N.J. , Aug. 4, 2015 ... with University of Massachusetts Medical School,s Clinical ... and support regarding clinical protocols and therapy ... Platform. Specialty medication therapy ... and helps to ensure optimal patient outcomes ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 2Armada Health Care collaborates with University of Massachusetts Medical School for ArmadaOne Specialty Pharmacy Platform 3
... Schering-Plough,Corporation (NYSE: SGP ), a leader in ... large Phase III studies of boceprevir, its,investigational oral ... hepatitis C virus (HCV) genotype 1. One study,will ... other in patients,who failed prior treatment (relapsers and ...
... Among Group of Leading Cancer Centers ... Presenting Cryoablation Data, ... ), an innovative medical device company focused on the,development of ... and tumor ablation, announced today,that cryoablation, a minimally invasive method ...
Cached Medicine Technology:Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 2Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 3Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 4Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 5Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 6Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 7Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 8Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 9Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment 10Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4
...
... antimony pH catheters are designed for patient comfort ... catheters are number marked at 5cm intervals and ... sixteen individual models are available spanning most clinical ... multi-use models with one or two sensors., ...
... designed using established technology providing a ... ,Working with pH catheters with ... multi-use catheter is used the Hellige ... the skin.,NOTE: ,Medtronic pH measurement systems ...
FLEXILOG spare part....
Medicine Products: